Clinical trialNCT04173650RecruitingPhase 1/PHASE2Interventional

MSC EVs in Dystrophic Epidermolysis Bullosa

SponsorAegle TherapeuticsEnrollment8Dystrophic Epidermolysis Bullosa

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

INVESTIGATIONAL PRODUCT: AGLE-102 is an allogeneic extracellular vesicle (EV) product derived from normal donor mesenchymal stem cells (MSCs). INDICATION AND RATIONALE: The aim of the study is to assess the safety and efficacy of AGLE-102 in the treatment of lesions in subjects with Epidermolysis Bullosa (EB). STUDY DESIGN: This is a phase 1/2A, randomized, multi-center, study to assess the effectiveness and safety of AGLE-102 on lesions in subjects with EB.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

David T Woodley, MD
University of Southern California Dept of Dermatology
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Phoenix Children'S Hospital
Phoenix, Arizona, United States
Harper N Price, MD, FAAD, FAAP
Recruiting
Usc /norris Comprehensive Cancer Center University of Southern California
Los Angeles, California, United States
David Woodley, MD
Recruiting
Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Marissa Perman, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AGLE-102

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 13 Aug 2024
Primary completion: 30 Sept 2025
Completion: 31 Mar 2026
Last update posted: 25 Jun 2025
Registered enrollment: 8
Registry id: NCT04173650

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 30 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.